Immune therapy targets cells that cause leukemia relapse



Immune therapy targets cells that cause leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study. The new cell therapy, now being tested in phase 1 clinical trials, may ultimately help patients with AML to remain cancer-free.

Materials provided by Weill Cornell Medicine. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

31st March 2023

Form is (mal)function: Protein's shape lets bacteria disarm it

Read more
30th March 2023

Researchers discover a way to fight the aging process and cancer development

Read more
30th March 2023

Researchers identify cell type that could be key to preventing marrow transplant complication

Read more